10/14/2026
🌿WELLNESS WEDNESDAY 🌿 | BODY
Peptides: Promise, Precaution, and What Comes Next
Peptides are getting plenty of attention for healing, recovery, and longevity. But what do we actually know, and what is happening at the FDA?
On July 23–24, an FDA advisory committee narrowly voted (margins ranged from 7–4 to 8–6) to recommend that six unapproved peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon) be added to the list of ingredients pharmacies may use for patient-specific compounding. A seventh, emideltide (DSIP), was not recommended. The committee looked at specific uses, such as BPC-157 for ulcerative colitis and Epitalon for insomnia, not broad claims like recovery or anti-aging.
That recommendation is not FDA approval, and it does not make these peptides legal to compound today. The FDA would still need to propose and finalize a rule. As of mid-October, no formal FDA action has been announced, though news reports say the administration is considering temporary access while rules are written.
FDA scientists recommended against adding all seven peptides. Their briefing documents cited limited human data for the uses reviewed, and questions about whether products consistently contain what their labels claim, whether unwanted manufacturing byproducts remain, and whether peptide molecules clump together into tiny clusters that could trigger an immune response.
That does not mean these peptides have been proven harmful or ineffective. It means important questions remain unanswered.
There is another side to this discussion: people are already using these products, often bought online as "research use only" with no guarantee of purity or dose. Supporters argue that access through licensed pharmacies and clinicians could offer better oversight than that gray market. Critics worry about bypassing clinical trials and setting a precedent, and some raised concerns about conflicts of interest on the panel.
Widespread use alone cannot tell us how well a treatment works or how often complications occur. We need consistent product testing and reliable patient follow-up.
A reasonable path forward could pair controlled access with independent quality testing, clear patient education, and systematic tracking of benefits and side effects, alongside clinical trials.
A note for athletes: BPC-157 and TB-500 are prohibited under World Anti-Doping Agency rules, whether or not a pharmacy can compound them.
As a physician, I see value in investigating new treatments carefully and asking thoughtful questions about the evidence. If you are considering peptides, talk with your clinician first.
Hope deserves investigation. Our health deserves informed decisions.
